LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network owned and operated outpatient imaging centers, today announced that Gregory Sorensen, M.D., Chief Science Officer of RadNet and President of DeepHealth (RadNet’s Artificial Intelligence Division) and Sham Sokka, Chief Operating & Technology Officer of RadNet’s Digital Health, will be presenting at the Cowen & Company Healthcare Conference on Wednesday, March 6, 2024 at 2:10 p.m. Eastern Time.
There will be simultaneous and archived webcasts available here and www.radnet.com under the “About RadNet” menu section and “News and Press Releases” sub-menu of the website.
Details for RadNet’s Presentation: | |
Date: Time: URL: | Wednesday, March 6, 2024 2:10 p.m. Eastern Time /webcast/cowen154/register.aspx?conf=cowen154&page=rdnt&url=https://wsw.com/webcast/cowen154/rdnt/2031632 |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,700 employees. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
Last Trade: | US$73.78 |
Daily Change: | 2.06 2.87 |
Daily Volume: | 147,767 |
Market Cap: | US$5.680B |
September 26, 2025 September 08, 2025 August 07, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load